Predict Antidepressant Responsiveness Using Pharmacogenomics

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether genetic information associated with individual depressive symptoms.

Detailed Description
-----------------
The primary hypothesis is that the variations of the candidate genes are associated with individual symptoms in patients with depression. The Second hypothesis is that patients with the associated genetic variation suffer longer from the associated symptom than the patients without the associated genetic variation.

Official Title
-----------------
Predict Antidepressant Responsiveness Using Pharmacogenomics

Conditions
-----------------
Depression, Depressive Symptoms

Intervention / Treatment
-----------------
* Drug: SSRI treated group
* Drug: non-SSRI treated group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians Exclusion Criteria: received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SSRI treated group<br>SSRI treated group is patients treated with fluoxetine, paroxetine, or sertraline | Drug: SSRI treated group<br>* Antidepressant administration of SSRI class for 12 weeks under therapeutic dose<br>* Other names: sertraline_Zoloft;|
| Active Comparator: non-SSRI treated group<br>non-SSRI treated group is patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine | Drug: non-SSRI treated group<br>* Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose<br>* Other names: mirtazapine_Avanza, Zispin, Remeron;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presences of each individual symptom of depression at 1,2,4,6,12 weeks | 17-items HAM-D scale was employed to measure depressive symptoms | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmacogenomics, Depressed Patients